289 related articles for article (PubMed ID: 23500281)
1. Risk factor control for coronary artery disease secondary prevention in large randomized trials.
Farkouh ME; Boden WE; Bittner V; Muratov V; Hartigan P; Ogdie M; Bertolet M; Mathewkutty S; Teo K; Maron DJ; Sethi SS; Domanski M; Frye RL; Fuster V
J Am Coll Cardiol; 2013 Apr; 61(15):1607-15. PubMed ID: 23500281
[TBL] [Abstract][Full Text] [Related]
2. Baseline characteristics of patients with diabetes and coronary artery disease enrolled in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.
Bypass Angioplasty Revascularization Investigation 2 Diabetes Study Group
Am Heart J; 2008 Sep; 156(3):528-536, 536.e1-5. PubMed ID: 18760137
[TBL] [Abstract][Full Text] [Related]
3. Sex differences in presentation and outcome among patients with type 2 diabetes and coronary artery disease treated with contemporary medical therapy with or without prompt revascularization: a report from the BARI 2D Trial (Bypass Angioplasty Revascularization Investigation 2 Diabetes).
Tamis-Holland JE; Lu J; Korytkowski M; Magee M; Rogers WJ; Lopes N; Mighton L; Jacobs AK;
J Am Coll Cardiol; 2013 Apr; 61(17):1767-76. PubMed ID: 23500245
[TBL] [Abstract][Full Text] [Related]
4. Clinical implications of the BARI 2D and COURAGE trials: overview.
Brooks MM; Boden WE; Frye RL
Coron Artery Dis; 2010 Nov; 21(7):383-5. PubMed ID: 20664331
[TBL] [Abstract][Full Text] [Related]
5. The effect of age on clinical outcomes and health status BARI 2D (Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes).
Chung SC; Hlatky MA; Faxon D; Ramanathan K; Adler D; Mooradian A; Rihal C; Stone RA; Bromberger JT; Kelsey SF; Brooks MM;
J Am Coll Cardiol; 2011 Aug; 58(8):810-9. PubMed ID: 21835316
[TBL] [Abstract][Full Text] [Related]
6. Clinical implications of the BARI 2D and COURAGE trials of coronary artery disease.
Kuller LH
Coron Artery Dis; 2010 Nov; 21(7):391-6. PubMed ID: 20634693
[TBL] [Abstract][Full Text] [Related]
7. Factors related to the selection of surgical versus percutaneous revascularization in diabetic patients with multivessel coronary artery disease in the BARI 2D (Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes) trial.
Kim LJ; King SB; Kent K; Brooks MM; Kip KE; Abbott JD; Jacobs AK; Rihal C; Hueb WA; Alderman E; Sing IR; Attubato MJ; Feit F;
JACC Cardiovasc Interv; 2009 May; 2(5):384-92. PubMed ID: 19463459
[TBL] [Abstract][Full Text] [Related]
8. Health status after treatment for coronary artery disease and type 2 diabetes mellitus in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial.
Brooks MM; Chung SC; Helmy T; Hillegass WB; Escobedo J; Melsop KA; Massaro EM; McBane RD; Hyde P; Hlatky MA;
Circulation; 2010 Oct; 122(17):1690-9. PubMed ID: 20937978
[TBL] [Abstract][Full Text] [Related]
9. Lifestyle, Glycosylated Hemoglobin A1c, and Survival Among Patients With Stable Ischemic Heart Disease and Diabetes.
Mancini GBJ; Maron DJ; Hartigan PM; Spertus JA; Kostuk WJ; Berman DS; Teo KK; Weintraub WS; Boden WE;
J Am Coll Cardiol; 2019 Apr; 73(16):2049-2058. PubMed ID: 31023428
[TBL] [Abstract][Full Text] [Related]
10. Rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.
Bach RG; Brooks MM; Lombardero M; Genuth S; Donner TW; Garber A; Kennedy L; Monrad ES; Pop-Busui R; Kelsey SF; Frye RL;
Circulation; 2013 Aug; 128(8):785-94. PubMed ID: 23857320
[TBL] [Abstract][Full Text] [Related]
11. Clinical implications of the BARI 2D and COURAGE trials: the evolving role of percutaneous coronary intervention.
Holper EM; Addo T
Coron Artery Dis; 2010 Nov; 21(7):397-401. PubMed ID: 20634692
[TBL] [Abstract][Full Text] [Related]
12. Baseline coronary angiographic findings in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial (BARI 2D).
Schwartz L; Kip KE; Alderman E; Lu J; Bates ER; Srinivas V; Bach RG; Mighton LD; Feit F; King S; Frye RL;
Am J Cardiol; 2009 Mar; 103(5):632-8. PubMed ID: 19231325
[TBL] [Abstract][Full Text] [Related]
13. Optimal medical therapy with or without percutaneous coronary intervention in older patients with stable coronary disease: a pre-specified subset analysis of the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive druG Evaluation) trial.
Teo KK; Sedlis SP; Boden WE; O'Rourke RA; Maron DJ; Hartigan PM; Dada M; Gupta V; Spertus JA; Kostuk WJ; Berman DS; Shaw LJ; Chaitman BR; Mancini GB; Weintraub WS;
J Am Coll Cardiol; 2009 Sep; 54(14):1303-8. PubMed ID: 19778673
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of diabetic peripheral neuropathy and relation to glycemic control therapies at baseline in the BARI 2D cohort.
Pop-Busui R; Lu J; Lopes N; Jones TL;
J Peripher Nerv Syst; 2009 Mar; 14(1):1-13. PubMed ID: 19335534
[TBL] [Abstract][Full Text] [Related]
15. Clinical and angiographic risk stratification and differential impact on treatment outcomes in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.
Brooks MM; Chaitman BR; Nesto RW; Hardison RM; Feit F; Gersh BJ; Krone RJ; Sako EY; Rogers WJ; Garber AJ; King SB; Davidson CJ; Ikeno F; Frye RL;
Circulation; 2012 Oct; 126(17):2115-24. PubMed ID: 23008442
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive Cardiovascular Risk Factor Control Improves Survival: The BARI 2D Trial.
Bittner V; Bertolet M; Barraza Felix R; Farkouh ME; Goldberg S; Ramanathan KB; Redmon JB; Sperling L; Rutter MK;
J Am Coll Cardiol; 2015 Aug; 66(7):765-773. PubMed ID: 26271057
[TBL] [Abstract][Full Text] [Related]
17. Increased Hazard of Myocardial Infarction With Insulin-Provision Therapy in Actively Smoking Patients With Diabetes Mellitus and Stable Ischemic Heart Disease: The BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) Trial.
Khan AA; Chung MJ; Novak E; Brown DL
J Am Heart Assoc; 2017 Sep; 6(9):. PubMed ID: 28903941
[TBL] [Abstract][Full Text] [Related]
18. Intensive multifactorial intervention for stable coronary artery disease: optimal medical therapy in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial.
Maron DJ; Boden WE; O'Rourke RA; Hartigan PM; Calfas KJ; Mancini GB; Spertus JA; Dada M; Kostuk WJ; Knudtson M; Harris CL; Sedlis SP; Zoble RG; Title LM; Gosselin G; Nawaz S; Gau GT; Blaustein AS; Bates ER; Shaw LJ; Berman DS; Chaitman BR; Weintraub WS; Teo KK;
J Am Coll Cardiol; 2010 Mar; 55(13):1348-58. PubMed ID: 20338496
[TBL] [Abstract][Full Text] [Related]
19. Strategies for glycemic control in nonobese and obese type 2 diabetic patients with coronary artery disease.
Tsujimoto T; Kajio H
Int J Cardiol; 2019 May; 282():1-6. PubMed ID: 30772014
[TBL] [Abstract][Full Text] [Related]
20. Effect of glycemic and lipid achievements on clinical outcomes type 2 diabetic, Chinese patients with stable coronary artery disease.
Li S; Zhang Y; Guo YL; Zhu CG; Wu NQ; Qing P; Gao Y; Sun J; Liu G; Dong Q; Li JJ
J Diabetes Complications; 2016; 30(1):115-20. PubMed ID: 26481154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
